Sana Biotechnology reports Q4 net loss $88.1M; cash $205M; raises $190M in Feb; 40-60 patients in 2024

Sana Biotechnology, Inc.

2023-FY EPS reported -$1.46

Q4 2023 net loss $88.1M ($0.45/share); full year net loss $283.3M ($1.46/share).
Cash $205.2M at Dec 31, 2023; Feb 2024 offering raised $189.8M gross proceeds to fund pipeline.
Plans to treat 40-60 patients in 2024 across 4 trials in oncology, autoimmune, and type 1 diabetes.
Early SC291 data safe, immune evasion, early efficacy; IND cleared for SC291 in autoimmune and SC262 in B-cell malignancies.
Appointed Doug Williams President R&D, Gary Meininger CMO; expects 2024 operating burn <$200M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sana Biotechnology, Inc. reported financial results for the quarter and year ended December 31, 2023.

Period: the quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 29, 2024, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Sana Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-023083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.